March 2015 | Intellectual Property Today

Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc.: Where Does Claim Construction Go From Here?

1 min

Dominick Conde analyzes the Supreme Court’s January 20th, 2015 decision in Teva Pharmaceuticals v. Sandoz, which overturned the Federal Circuit’s de novo standard of review for district court claim constructions, and its implications on future patent litigations.